The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics may also be considered.

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

Number 5: Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of ...

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, ...

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for ...

Alvotech faces challenges with potential tariffs and profitability, despite strong revenue growth and a robust pipeline. See ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The results of an open-label extension study confirmed the interchangeability of biosimilar CT-917 with reference adalimumab for plaque psoriasis.

Patients with IBD treated with the original adalimumab reference product show a high acceptance of the switch to its ...

Sandoz (SIX: SDZ) shares slid around 3% Wednesday after the Swiss drugmaker reported first-quarter 2025 sales that came in 5% ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE <li /> Q1 2025 net sal ...

TNF Indicates Likelihood of Patient Response to Costly IBD Treatment Before Initiation of Therapy SAN DIEGO, CA / ACCESS ...